Icon Wealth Advisors LLC Trims Stock Position in Novo Nordisk A/S (NYSE:NVO)

Icon Wealth Advisors LLC decreased its holdings in Novo Nordisk A/S (NYSE:NVO) by 4.2% in the 3rd quarter, Holdings Channel reports. The firm owned 38,680 shares of the company’s stock after selling 1,686 shares during the period. Icon Wealth Advisors LLC’s holdings in Novo Nordisk A/S were worth $4,606,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently bought and sold shares of the company. 1620 Investment Advisors Inc. purchased a new position in Novo Nordisk A/S during the 2nd quarter worth $25,000. Strategic Investment Solutions Inc. IL purchased a new position in shares of Novo Nordisk A/S during the second quarter valued at approximately $25,000. Gilliland Jeter Wealth Management LLC grew its position in shares of Novo Nordisk A/S by 200.0% in the second quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock valued at $26,000 after purchasing an additional 120 shares during the period. Daiwa Securities Group Inc. purchased a new stake in Novo Nordisk A/S in the third quarter valued at approximately $28,000. Finally, Halpern Financial Inc. increased its holdings in shares of Novo Nordisk A/S by 113.0% during the 2nd quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock worth $30,000 after buying an additional 113 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. BMO Capital Markets lowered their price target on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $144.50.

Novo Nordisk A/S Stock Performance

Novo Nordisk A/S stock opened at $106.13 on Friday. Novo Nordisk A/S has a 1 year low of $94.73 and a 1 year high of $148.15. The company has a market cap of $476.26 billion, a PE ratio of 34.35, a PEG ratio of 1.37 and a beta of 0.42. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The company’s 50-day moving average is $113.22 and its two-hundred day moving average is $128.18.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.